Journal
NEUROSCIENCE
Volume 490, Issue -, Pages 309-314Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2022.03.010
Keywords
gene therapy; inducible promoters; epilepsy; microRNA; genetic therapy
Categories
Funding
- Epilepsy Research UK [F2102]
- Emerging Leader Fellowship Award from Epilepsy Research UK [F2102]
- MRC
- University Research Fellowship from the Royal Society
Ask authors/readers for more resources
Gene therapy is showing promise in treating rare monogenetic neurological disorders and could potentially offer new treatments for common non-genetic disorders as well. However, the permanent nature of gene therapies may pose risks, and research is being conducted to develop approaches that allow for treatment to be turned on and off.
Gene therapy for rare monogenetic neurological disorders is reaching clinics and offering hope to families affected by these diseases. There is also potential for gene therapy to offer new and effective treatments for common, non-genetic disorders. Treatments for Parkinson's Disease are in clinical trials, and treatments for refractory epilepsies are due to enter first-in-human clinical trials in 2022. Gene therapies for these disorders are based on delivering genes that address the mechanism of the disease, not repairing a mutated gene. Similar 'mechanistic' gene therapies could offer treatments to a wide range of neurological and neuropsychiatric diseases where there is a known mechanism that could be restored using gene therapy. However, the permanent nature of most gene therapies is a serious drawback for translation of gene therapies to a wide-range of diseases because it could present risk of irreversible adverse effects. Several lines of research are aimed at developing gene therapy approaches that allow for the treatment to be turned on and off, including: using proteins activated by exogenous ligands, and promoters turned on by activators. We review these approaches and propose an overall de-risking strategy for gene therapy for common neurological and psychiatric diseases. This approach is based on using a temporary mRNA-based treatment to initially assess efficacy and safety of the planned manipulation, and only following with permanent, virally-delivered treatment if the approach appears safe and effective. (c) 2022 Published by Elsevier Ltd on behalf of IBRO.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available